Published in Mol Carcinog on January 01, 1992
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol (2002) 2.12
Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res (2009) 1.29
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res (2010) 1.17
Evolution and expression of chimeric POTE-actin genes in the human genome. Proc Natl Acad Sci U S A (2006) 1.09
p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol (1995) 1.08
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol (2012) 0.98
Is the small heat shock protein alphaB-crystallin an oncogene? J Clin Invest (2006) 0.93
The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids. Br J Cancer (1995) 0.92
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget (2015) 0.84
Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS One (2014) 0.82
Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis. Oncogene (2014) 0.82
Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. Br J Cancer (1996) 0.80
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia (2013) 0.78
The role of transforming growth factor alpha production and ErbB-2 overexpression in induction of tumorigenicity of lung epithelial cells. Br J Cancer (1998) 0.75
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res (2000) 3.95
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Multicolour spectral karyotyping of mouse chromosomes. Nat Genet (1996) 2.90
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab (2015) 2.41
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res (2001) 2.29
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer (2000) 2.14
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14
Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes. Nat Cell Biol (2001) 2.14
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol (2009) 2.13
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev (1987) 2.07
Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet (1999) 1.98
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem (1999) 1.93
Demonstration that monocytes rather than lymphocytes are the insulin-binding cells in preparations of humah peripheral blood mononuclear leukocytes: implications for studies of insulin-resistant states in man. Proc Natl Acad Sci U S A (1975) 1.83
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res (2000) 1.82
Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer (2011) 1.78
Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin. Proc Natl Acad Sci U S A (1982) 1.76
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol (1996) 1.74
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid (2001) 1.73
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Differential response to growth factor by rat mammary epithelium plated on different collagen substrata in serum-free medium. Proc Natl Acad Sci U S A (1981) 1.69
Isolation and characterization of a highly enriched preparation of receptosomes (endosomes) from a human cell line. Proc Natl Acad Sci U S A (1983) 1.68
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer (2003) 1.67
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res (1999) 1.66
Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol (1994) 1.65
Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem (1999) 1.62
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets (2005) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol (2001) 1.57
Surgery plus adjuvant chemotherapy for T1-3N0M0 small-cell lung cancer. Rationale for current approach. Am J Clin Oncol (1991) 1.56
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54
Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J Biol Chem (1994) 1.53
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) (2011) 1.52
Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A (1991) 1.52
Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol (2001) 1.52
Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology. J Clin Endocrinol Metab (2010) 1.50
Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer (2009) 1.49
Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem (2001) 1.49
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis. Biochemistry (1983) 1.46
Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol (1991) 1.45
The role of EGF-related peptides in tumor growth. Front Biosci (2001) 1.45
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 1.43
Plasma and tissue chromogranin in patients with adrenocortical adenomas. J Endocrinol Invest (2004) 1.42
Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (1986) 1.41
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41
Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol (1995) 1.40
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem (1997) 1.36
Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst (1992) 1.36
Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. Cell Growth Differ (1990) 1.36
Receptor-mediated endocytosis in cultured fibroblasts: cryptic coated pits and the formation of receptosomes. J Histochem Cytochem (1981) 1.35
cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol (1995) 1.33
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab (2001) 1.31
Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clin Endocrinol (Oxf) (2007) 1.30
Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene (2000) 1.29
Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer (1995) 1.27
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer (1995) 1.27
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? Eur J Cancer (1996) 1.26
A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer (1999) 1.26
Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells. Mol Cell Biol (1990) 1.26
Estrogen receptor in adult male rat liver. Endocrinology (1978) 1.26
The dioxygen adduct of meso-tetraphenylporphyrinmanganese(II), a synthetic oxygen carrier. J Am Chem Soc (1976) 1.25
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol (2005) 1.24
Specific receptors for phorbol esters in lymphoid cell populations: role in enhanced production of T-cell growth factor. Proc Natl Acad Sci U S A (1981) 1.24
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer (2000) 1.22
Presence of transforming growth factors in human breast cancer cells. Cancer Res (1984) 1.21
Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology (1986) 1.19
Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer (1995) 1.19
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer (2002) 1.19
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol (2006) 1.18
Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer (1992) 1.17
Binding and internalization of 125I-alpha 2-macroglobulin by cultured fibroblasts. J Biol Chem (1981) 1.17
Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res (1992) 1.17
Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res (1990) 1.16
Steroid receptors and steroid response in cultured L1210 murine leukemia cells. Mol Cell Endocrinol (1979) 1.15
Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. Eur J Endocrinol (2010) 1.15
Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res (1993) 1.14
Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol (1992) 1.13
Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol (2011) 1.13
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (1996) 1.13
Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ (1999) 1.13